Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kohei Shitara

Showing results (201-210 of 344) with videos related to

Pageof 35
Sort By:
The Lancet. Oncology|August 2, 2017
TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 studyYasutoshi Kuboki, Tomohiro Nishina, Eiji Shinozaki, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|May 4, 2017
Phase 1 study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407)Kohei Shitara, Toshihiko Doi, Osamu Nagano, et al.
Immunity|July 9, 2020
An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T CellsShogo Kumagai, Yosuke Togashi, Chika Sakai, et al.
Investigational New Drugs|June 22, 2020
The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434)Toshihiko Doi, Yutaka Fujiwara, Kohei Shitara, et al.
Cancer Medicine|October 16, 2021
Clinical implications of using both fluoropyrimidine and paclitaxel in patients with severe peritoneal metastasis of gastric cancer: A post hoc study of JCOG1108/WJOG7312GHiroyuki Arai, Eisuke Inoue, Kensei Yamaguchi, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 18, 2011
ABO genotype and the risk of gastric cancer, atrophic gastritis, and Helicobacter pylori infectionMakoto Nakao, Keitaro Matsuo, Hidemi Ito, et al.
Cancer Immunology Research|March 6, 2021
Transient Depletion of CD4<sup>+</sup> Cells Induces Remodeling of the TCR Repertoire in Gastrointestinal CancerHiroyasu Aoki, Satoshi Ueha, Shigeyuki Shichino, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 28, 2019
PD-1<sup>+</sup> regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancerTakahiro Kamada, Yosuke Togashi, Christopher Tay, et al.
International Journal of Cancer|July 8, 2009
Association of prostate stem cell antigen gene polymorphisms with the risk of stomach cancer in JapaneseKeitaro Matsuo, Kazuo Tajima, Takeshi Suzuki, et al.
Oncotarget|November 8, 2017
Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with <i>MET</i>-amplified gastric cancerKohei Shitara, Tae Min Kim, Tomoya Yokota, et al.
Pageof 35

Showing results (201-210 of 344) with videos related to

Sort By:
Pageof 35
The Lancet. Oncology|August 2, 2017
TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 studyYasutoshi Kuboki, Tomohiro Nishina, Eiji Shinozaki, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|May 4, 2017
Phase 1 study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407)Kohei Shitara, Toshihiko Doi, Osamu Nagano, et al.
Immunity|July 9, 2020
An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T CellsShogo Kumagai, Yosuke Togashi, Chika Sakai, et al.
Investigational New Drugs|June 22, 2020
The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434)Toshihiko Doi, Yutaka Fujiwara, Kohei Shitara, et al.
Cancer Medicine|October 16, 2021
Clinical implications of using both fluoropyrimidine and paclitaxel in patients with severe peritoneal metastasis of gastric cancer: A post hoc study of JCOG1108/WJOG7312GHiroyuki Arai, Eisuke Inoue, Kensei Yamaguchi, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 18, 2011
ABO genotype and the risk of gastric cancer, atrophic gastritis, and Helicobacter pylori infectionMakoto Nakao, Keitaro Matsuo, Hidemi Ito, et al.
Cancer Immunology Research|March 6, 2021
Transient Depletion of CD4<sup>+</sup> Cells Induces Remodeling of the TCR Repertoire in Gastrointestinal CancerHiroyasu Aoki, Satoshi Ueha, Shigeyuki Shichino, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 28, 2019
PD-1<sup>+</sup> regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancerTakahiro Kamada, Yosuke Togashi, Christopher Tay, et al.
International Journal of Cancer|July 8, 2009
Association of prostate stem cell antigen gene polymorphisms with the risk of stomach cancer in JapaneseKeitaro Matsuo, Kazuo Tajima, Takeshi Suzuki, et al.
Oncotarget|November 8, 2017
Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with <i>MET</i>-amplified gastric cancerKohei Shitara, Tae Min Kim, Tomoya Yokota, et al.
Pageof 35